<p>Rapt Therapeutics（纳斯达克代码：RAPT - 获取免费报告）在周三的交易量有所上升。当天中午交易中，交易了 297,424 股，较前一交易日的 198,388 股增加了 50%。该股票最后交易价格为 31.5770 美元，之前收盘价为 29.97 美元。</p>
<p>获取 <strong>Rapt Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<p>几位分析师最近对该公司进行了评论。华尔街 Zen 在 9 月 13 日的报告中将 Rapt Therapeutics 的评级从 “卖出” 上调至 “持有”。Leerink Partners 在 9 月 26 日的报告中将 Rapt Therapeutics 的评级从 “市场表现” 上调至 “跑赢大盘”，并将该公司的目标价格从 16.00 美元上调至 37.00 美元。Guggenheim 在 10 月 27 日的研究报告中开始覆盖 Rapt Therapeutics，给予该股票 “买入” 评级，目标价格为 70.00 美元。摩根大通在 11 月 12 日的研究报告中将 Rapt Therapeutics 的目标价格从 55.00 美元上调至 57.00 美元，并给予该公司 “增持” 评级。最后，瑞银集团在 8 月 12 日的研究报告中设定了 Rapt Therapeutics 的目标价格为 9.00 美元，并给予该股票 “中性” 评级。两位研究分析师给予该股票 “强烈买入” 评级，六位给予 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，Rapt Therapeutics 目前的平均评级为 “适度买入”，共识目标价格为 50.50 美元。</p>
<p><strong>查看我们关于 Rapt Therapeutics 的最新股票报告</strong></p>
<h2>Rapt Therapeutics 股票上涨 9.4%</h2>
<p>该公司的市值为 9.0872 亿美元，市盈率为-2.96，贝塔值为 0.20。该公司的 50 日简单移动平均为 27.78 美元，200 日简单移动平均为 16.24 美元。</p>
<p>Rapt Therapeutics（纳斯达克代码：RAPT - 获取免费报告）最近在 11 月 6 日发布了季度财报。该公司报告每股收益为（0.65 美元），超出市场共识预期的（0.88 美元）0.23 美元。平均而言，卖方分析师预计 Rapt Therapeutics 在当前财政年度的每股收益为-2.14 美元。</p>
<h2>机构投资者对 Rapt Therapeutics 的看法</h2>
<p>一些对冲基金最近买入和卖出了 RAPT 的股票。Bridgeway Capital Management LLC 在第三季度将其在 Rapt Therapeutics 的持股增加了 32.0%。Bridgeway Capital Management LLC 目前拥有 20,625 股该公司的股票，价值 532,000 美元，此前在此期间又增持了 5,000 股。Dimensional Fund Advisors LP 在第三季度购买了 Rapt Therapeutics 的新头寸，价值 231,000 美元。Millennium Management LLC 在第三季度将其在 Rapt Therapeutics 的持股增加了 75.2%。Millennium Management LLC 目前拥有 39,278 股该公司的股票，价值 1,013,000 美元，此前在此期间又增持了 16,854 股。瑞银集团在第三季度将其在 Rapt Therapeutics 的持股增加了 680.3%。瑞银集团目前拥有 28,808 股该公司的股票，价值 743,000 美元，此前在上个季度又增持了 25,116 股。最后，Susquehanna International Group LLP 在第三季度将其在 Rapt Therapeutics 的持股增加了 173.4%。Susquehanna International Group LLP 目前拥有 45,382 股该公司的股票，价值 1,170,000 美元，此前在此期间又增持了 28,782 股。对冲基金和其他机构投资者持有该公司 99.09% 的股票。</p>
<h2>关于 Rapt Therapeutics</h2>
<p>（获取免费报告）</p>
<p>RAPT Therapeutics, Inc 是一家临床阶段的基于免疫学的生物制药公司，专注于发现、开发和商业化针对美国肿瘤和炎症疾病患者未满足需求的口服小分子疗法。该公司的主要炎症药物候选者是 zelnecirnon（RPT193），这是一种 C-C 基序趋化因子受体 4（CCR4）拮抗剂，选择性抑制 2 型 T 辅助细胞向炎症组织的迁移。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Rapt Therapeutics</li>
<li>股票行业对成功投资的重要性</li>
<li>微软股票面临 AI 驱动的物理问题</li>
<li>什么是收益惊喜？</li>
<li>是时候投资于孩子最喜欢的游戏平台了吗？</li>
<li>2022-2025 年股票市场假期 - 纽约证券交易所和纳斯达克将关闭的时间</li>
<li>在圣诞老人来之前要买的 5 只股票</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Rapt Therapeutics 吗？</h2>
<p>在你考虑 Rapt Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Rapt Therapeutics 并不在名单上。</p>
<p>虽然 Rapt Therapeutics 目前在分析师中有适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

RAPT

<p>RAPT Therapeutics（纳斯达克代码：RAPT）的交易量增加了 50%，股价上涨至 31.5770 美元。分析师们已上调了该股票的评级，Guggenheim 给予 “买入” 评级，并设定 70 美元的目标价。该公司报告的季度收益超出预期，机构投资者增加了持股。RAPT Therapeutics 专注于开发肿瘤和炎症疾病的治疗方案。该股票的平均评级为 “适度买入”，共识目标价为 50.50 美元</p>

<p>Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) shares saw an uptick in trading volume on Wednesday . 297,424 shares were traded during mid-day trading, an increase of 50% from the previous session's volume of 198,388 shares.The stock last traded at $31.5770 and had previously closed at $29.97.</p>
<div class="lb-trans"><p>Rapt Therapeutics（纳斯达克代码：RAPT - 获取免费报告）在周三的交易量有所上升。当天中午交易中，交易了 297,424 股，较前一交易日的 198,388 股增加了 50%。该股票最后交易价格为 31.5770 美元，之前收盘价为 29.97 美元。</p>
</div><p>Get <strong>Rapt Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Rapt Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several analysts recently commented on the company. Wall Street Zen upgraded Rapt Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, September 13th. Leerink Partners raised Rapt Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and upped their target price for the company from $16.00 to $37.00 in a report on Friday, September 26th. Guggenheim began coverage on Rapt Therapeutics in a research note on Monday, October 27th. They issued a &#34;buy&#34; rating and a $70.00 price objective on the stock. JPMorgan Chase &amp; Co. lifted their price objective on shares of Rapt Therapeutics from $55.00 to $57.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, November 12th. Finally, UBS Group set a $9.00 price objective on Rapt Therapeutics and gave the stock a &#34;neutral&#34; rating in a research report on Tuesday, August 12th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Rapt Therapeutics currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $50.50.</p>
<div class="lb-trans"><p>几位分析师最近对该公司进行了评论。华尔街 Zen 在 9 月 13 日的报告中将 Rapt Therapeutics 的评级从 “卖出” 上调至 “持有”。Leerink Partners 在 9 月 26 日的报告中将 Rapt Therapeutics 的评级从 “市场表现” 上调至 “跑赢大盘”，并将该公司的目标价格从 16.00 美元上调至 37.00 美元。Guggenheim 在 10 月 27 日的研究报告中开始覆盖 Rapt Therapeutics，给予该股票 “买入” 评级，目标价格为 70.00 美元。摩根大通在 11 月 12 日的研究报告中将 Rapt Therapeutics 的目标价格从 55.00 美元上调至 57.00 美元，并给予该公司 “增持” 评级。最后，瑞银集团在 8 月 12 日的研究报告中设定了 Rapt Therapeutics 的目标价格为 9.00 美元，并给予该股票 “中性” 评级。两位研究分析师给予该股票 “强烈买入” 评级，六位给予 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，Rapt Therapeutics 目前的平均评级为 “适度买入”，共识目标价格为 50.50 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Rapt Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Rapt Therapeutics 的最新股票报告</strong></p>
</div><h2>Rapt Therapeutics Stock Up 9.4%</h2>
<div class="lb-trans"><h2>Rapt Therapeutics 股票上涨 9.4%</h2>
</div><p>The firm has a market cap of $908.72 million, a P/E ratio of -2.96 and a beta of 0.20. The business has a fifty day simple moving average of $27.78 and a 200-day simple moving average of $16.24.</p>
<div class="lb-trans"><p>该公司的市值为 9.0872 亿美元，市盈率为-2.96，贝塔值为 0.20。该公司的 50 日简单移动平均为 27.78 美元，200 日简单移动平均为 16.24 美元。</p>
</div><p>Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.23. On average, sell-side analysts anticipate that Rapt Therapeutics will post -2.14 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Rapt Therapeutics（纳斯达克代码：RAPT - 获取免费报告）最近在 11 月 6 日发布了季度财报。该公司报告每股收益为（0.65 美元），超出市场共识预期的（0.88 美元）0.23 美元。平均而言，卖方分析师预计 Rapt Therapeutics 在当前财政年度的每股收益为-2.14 美元。</p>
</div><h2>Institutional Investors Weigh In On Rapt Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Rapt Therapeutics 的看法</h2>
</div><p>A number of hedge funds have recently bought and sold shares of RAPT. Bridgeway Capital Management LLC increased its holdings in shares of Rapt Therapeutics by 32.0% in the 3rd quarter. Bridgeway Capital Management LLC now owns 20,625 shares of the company's stock valued at $532,000 after acquiring an additional 5,000 shares during the period. Dimensional Fund Advisors LP purchased a new position in Rapt Therapeutics during the 3rd quarter worth $231,000. Millennium Management LLC increased its stake in Rapt Therapeutics by 75.2% in the third quarter. Millennium Management LLC now owns 39,278 shares of the company's stock valued at $1,013,000 after purchasing an additional 16,854 shares during the period. UBS Group AG raised its holdings in shares of Rapt Therapeutics by 680.3% in the third quarter. UBS Group AG now owns 28,808 shares of the company's stock valued at $743,000 after buying an additional 25,116 shares during the last quarter. Finally, Susquehanna International Group LLP boosted its stake in shares of Rapt Therapeutics by 173.4% during the third quarter. Susquehanna International Group LLP now owns 45,382 shares of the company's stock worth $1,170,000 after buying an additional 28,782 shares during the period. Hedge funds and other institutional investors own 99.09% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近买入和卖出了 RAPT 的股票。Bridgeway Capital Management LLC 在第三季度将其在 Rapt Therapeutics 的持股增加了 32.0%。Bridgeway Capital Management LLC 目前拥有 20,625 股该公司的股票，价值 532,000 美元，此前在此期间又增持了 5,000 股。Dimensional Fund Advisors LP 在第三季度购买了 Rapt Therapeutics 的新头寸，价值 231,000 美元。Millennium Management LLC 在第三季度将其在 Rapt Therapeutics 的持股增加了 75.2%。Millennium Management LLC 目前拥有 39,278 股该公司的股票，价值 1,013,000 美元，此前在此期间又增持了 16,854 股。瑞银集团在第三季度将其在 Rapt Therapeutics 的持股增加了 680.3%。瑞银集团目前拥有 28,808 股该公司的股票，价值 743,000 美元，此前在上个季度又增持了 25,116 股。最后，Susquehanna International Group LLP 在第三季度将其在 Rapt Therapeutics 的持股增加了 173.4%。Susquehanna International Group LLP 目前拥有 45,382 股该公司的股票，价值 1,170,000 美元，此前在此期间又增持了 28,782 股。对冲基金和其他机构投资者持有该公司 99.09% 的股票。</p>
</div><h2>About Rapt Therapeutics</h2>
<div class="lb-trans"><h2>关于 Rapt Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.</p>
<div class="lb-trans"><p>RAPT Therapeutics, Inc 是一家临床阶段的基于免疫学的生物制药公司，专注于发现、开发和商业化针对美国肿瘤和炎症疾病患者未满足需求的口服小分子疗法。该公司的主要炎症药物候选者是 zelnecirnon（RPT193），这是一种 C-C 基序趋化因子受体 4（CCR4）拮抗剂，选择性抑制 2 型 T 辅助细胞向炎症组织的迁移。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Rapt Therapeutics</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>Microsoft Stock Faces An AI-Driven Physics Problem</li>
<li>What is an Earnings Surprise?</li>
<li>Is It Time to Invest in Your Kid's Favorite Gaming Platform?</li>
<li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li>
<li>5 Stocks to Buy Before Santa Claus Comes to Town</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Rapt Therapeutics</li>
<li>股票行业对成功投资的重要性</li>
<li>微软股票面临 AI 驱动的物理问题</li>
<li>什么是收益惊喜？</li>
<li>是时候投资于孩子最喜欢的游戏平台了吗？</li>
<li>2022-2025 年股票市场假期 - 纽约证券交易所和纳斯达克将关闭的时间</li>
<li>在圣诞老人来之前要买的 5 只股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Rapt Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Rapt Therapeutics 吗？</h2>
</div><p>Before you consider Rapt Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Rapt Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapt Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Rapt Therapeutics 并不在名单上。</p>
</div><p>While Rapt Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Rapt Therapeutics 目前在分析师中有适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

RAPT Therapeutics（纳斯达克代码：RAPT）交易量强劲的原因